Molecular Imaging and Spectroscopy with Stable Isotopes in Oncology and Neurology: Imaging metabolism and tissue structure in Multiple Sclerosis with MRI (MISSION: MIMS)
Multiple sclerosis
Current methodology as of 27/02/2026: Up to 15 patients with MS will be successfully imaged following injection with 13C pyruvate. Up to 40 healthy volunteers will be successfully imaged following injection with 13C pyruvate. Up to 40 healthy volunteers will be recruited as part of the deuterium metabolic imaging (DMI) sub-study. Up to 35 patients with MS will be recruited as part of the deuterium metabolic imaging (DMI) sub-study. An optional second imaging study up to 14 days (HV) or 7 days (MS patients) later will be offered. Some of the participants will be asked to fast for 6 hours prior to the scan taking place. Previous methodology: Up to 15 patients with MS will be successfully imaged following injection with 13C pyruvate. Up to 40 healthy volunteers will be successfully imaged following injection with 13C pyruvate. An optional second imaging study up to 14 days later will be offered. Some of these volunteers will be asked to fast for 6 hours prior to the scan taking place. Up to 30 healthy volunteers will be recruited as part of the deuterium metabolic imaging (DMI) sub-study. Up to 15 patients with MS will be recruited as part of the deuterium metabolic imaging (DMI) sub-study.
MS patients (for C13 and DMI) 1. Be aged 18 years or older. 2. Have a confirmed diagnosis of MS. 3. Be aware of and understand their diagnosis. 4. Be able to provide written informed consent according to ICH/GCP, national and local regulations. 5. Be willing and able to comply with scheduled visits, laboratory tests, imaging and other study procedures. Healthy volunteers (C13 and DMI) 1. Be aged 18 years or older 2. Be able to provide written informed consent according to ICH/GCP, national and local regulations 3. Be willing and able to comply with scheduled visits, laboratory tests, imaging and other study procedures
MS patients (for C13 and DMI) 1. Have uncontrolled diabetes or glucose deranging conditions, or treatment that would cause such effects. 2. Have any medical condition that may increase the risk associated with study participation or in the judgement of the investigators make it unsuitable for the patient to enter the study. 3. Have a known allergy, adverse reaction or contraindication to any of the injected contrast agents used in this study including gadolinium contrast agents or pyruvate. 4. Be otherwise unsuitable for MRI e.g. having a permanent pacemaker, severe obesity or inability to lie still. 5. Be pregnant or breastfeeding Healthy volunteers (for C13 and DMI) 1. Have uncontrolled diabetes or glucose deranging conditions, or treatment that would cause such effects. The significance of this will be determined by the research team. 2. Have any medical condition that may increase the risk associated with study participation, or in the judgement of the investigators make it unsuitable for the patient to enter the study. 3. Have a known allergy, adverse reaction or contraindication to any of the injected contrast agents used in this study including gadolinium contrast agents or pyruvate. 4. Be otherwise unsuitable for MRI e.g. having a permanent pacemaker, severe obesity or inability to lie still. 5. Be pregnant or breastfeeding 6. Any previous or current neurological condition deemed to be significant by the research team.